Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
89.81 CHF | -0.63% | -3.82% | +5.82% |
Dec. 06 | Swiss Market Index Ends Week Little Changed; Holcim Shares Down | MT |
Dec. 06 | Novartis Reports 'Positive' Results From Phase 3 Study of Potential Blood Disorder Therapy | MT |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Net Income | 11.73B | 8.07B | 24.02B | 6.96B | 14.85B | |||||
Depreciation & Amortization - CF | 1.65B | 2.09B | 1.53B | 1.47B | 1.18B | |||||
Amortization of Goodwill and Intangible Assets - (CF) | 2.84B | 3.46B | 3.9B | 3.98B | 3.96B | |||||
Depreciation & Amortization, Total | 4.49B | 5.55B | 5.43B | 5.45B | 5.14B | |||||
(Gain) Loss From Sale Of Asset | -1.23B | -478M | -677M | -333M | -180M | |||||
(Gain) Loss on Sale of Investments - (CF) | -38M | -335M | -38M | 260M | 106M | |||||
Asset Writedown & Restructuring Costs | 1.34B | 914M | 684M | 1.73B | 3.14B | |||||
(Income) Loss On Equity Investments - (CF) | -659M | -673M | -15.34B | 9M | 15M | |||||
Stock-Based Compensation (CF) | 758M | 738M | 736M | 823M | 865M | |||||
Net Cash From Discontinued Operations | 78M | - | - | - | 238M | |||||
Other Operating Activities, Total | -2.11B | 2.59B | 1.13B | 1.23B | -7.81B | |||||
Change In Accounts Receivable | -980M | 137M | -389M | -589M | -1.5B | |||||
Change In Inventories | -382M | -543M | 81M | -830M | -546M | |||||
Change In Accounts Payable | 553M | -324M | -21M | -48M | 479M | |||||
Change in Other Net Operating Assets | 84M | -2B | -549M | -421M | -332M | |||||
Cash from Operations | 13.62B | 13.65B | 15.07B | 14.24B | 14.46B | |||||
Capital Expenditure | -1.38B | -1.28B | -1.38B | -1.2B | -1.06B | |||||
Sale of Property, Plant, and Equipment | 857M | 88M | 240M | 167M | 237M | |||||
Cash Acquisitions | -3.85B | -10.01B | -633M | -864M | -3.56B | |||||
Divestitures | 91M | 49M | 66M | -15M | 3M | |||||
Sale (Purchase) of Intangible assets | 95M | -930M | -845M | -1.27B | 262M | |||||
Investment in Marketable and Equity Securities, Total | 3.18B | -922M | 6.82B | 4.65B | 10.84B | |||||
Other Investing Activities, Total | -1.22B | -186M | -57M | -1M | -1.12B | |||||
Cash from Investing | -2.23B | -13.18B | 4.21B | 1.47B | 5.6B | |||||
Short Term Debt Issued, Total | - | 2.26B | - | 295M | 546M | |||||
Long-Term Debt Issued, Total | 93M | 7.13B | 16M | 16M | - | |||||
Total Debt Issued | 93M | 9.39B | 16M | 311M | 546M | |||||
Short Term Debt Repaid, Total | -1.58B | - | -3.52B | - | - | |||||
Long-Term Debt Repaid, Total | -3.47B | -2.32B | -2.48B | -2.87B | -2.48B | |||||
Total Debt Repaid | -5.05B | -2.32B | -6B | -2.87B | -2.48B | |||||
Issuance of Common Stock | 201M | 748M | 53M | 100M | 153M | |||||
Repurchase of Common Stock | -5.53B | -2.84B | -3.06B | -10.65B | -8.72B | |||||
Common Dividends Paid | -6.64B | -6.99B | -7.37B | -7.51B | -7.26B | |||||
Common & Preferred Stock Dividends Paid | -6.64B | -6.99B | -7.37B | -7.51B | -7.26B | |||||
Other Financing Activities, Total | 3.31B | -199M | 94M | 55M | 3.48B | |||||
Cash from Financing | -13.63B | -2.21B | -16.26B | -20.56B | -14.28B | |||||
Foreign Exchange Rate Adjustments | 69M | 286M | -266M | -32M | 100M | |||||
Net Change in Cash | -2.16B | -1.45B | 2.75B | -4.89B | 5.88B | |||||
Supplemental Items | ||||||||||
Cash Interest Paid | 793M | 703M | 664M | 696M | 751M | |||||
Cash Income Tax Paid (Refund) | 1.88B | 1.83B | 2.34B | 1.98B | 2.79B | |||||
Levered Free Cash Flow | 13.46B | 13.27B | 13.12B | 9.69B | 12.13B | |||||
Unlevered Free Cash Flow | 13.99B | 13.81B | 13.62B | 10.21B | 12.67B | |||||
Change In Net Working Capital | -2.63B | -1.89B | -1.42B | 1.85B | 713M | |||||
Net Debt Issued / Repaid | -4.96B | 7.07B | -5.99B | -2.56B | -1.94B |